Caribou Biosciences, Inc. (NASDAQ:CRBU – Get Free Report) CEO Rachel E. Haurwitz acquired 20,000 shares of Caribou Biosciences stock in a transaction that occurred on Friday, March 14th. The stock was purchased at an average cost of $1.02 per share, for a total transaction of $20,400.00. Following the completion of the transaction, the chief executive officer now directly owns 3,369,395 shares in the company, valued at $3,436,782.90. This trade represents a 0.60 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Caribou Biosciences Price Performance
Shares of CRBU stock opened at $1.02 on Tuesday. The company has a market capitalization of $94.87 million, a P/E ratio of -0.62 and a beta of 2.34. The company’s 50-day simple moving average is $1.35 and its two-hundred day simple moving average is $1.77. Caribou Biosciences, Inc. has a one year low of $0.98 and a one year high of $5.77.
Caribou Biosciences (NASDAQ:CRBU – Get Free Report) last issued its earnings results on Monday, March 10th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $2.08 million for the quarter, compared to the consensus estimate of $2.11 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. On average, research analysts expect that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.
Hedge Funds Weigh In On Caribou Biosciences
Analyst Ratings Changes
A number of analysts recently weighed in on CRBU shares. Bank of America reduced their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Citigroup reduced their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 26th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $10.33.
Check Out Our Latest Stock Analysis on Caribou Biosciences
About Caribou Biosciences
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Featured Stories
- Five stocks we like better than Caribou Biosciences
- What to Know About Investing in Penny Stocks
- Can TikTok Stock Picks Really Make You Rich?
- Investing in the High PE Growth Stocks
- The “Quality” Rotation: Back to Basics Investing
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.